

Annual General Meeting 11 November 2019



ANATARA
LIFESCIENCES

Advancing gastrointestinal health



Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.

Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Key Investor Message

More than ever, the world is looking for safe and effective solutions to gut health.

The Anataro team is focussed on delivering evidence-based, commercially attractive solutions for gastrointestinal diseases in animals and humans.



Corporate Fast Facts



Share Price
\$0.22*

ASX ticker code
ANR

Ordinary Shares
49,562,693

Market Capitalisation
\$10.9 million*

Options
2,571,000
Performance Rights
186,674

Cash
\$4.45 million[#]
Quarter cash burn
\$0.95 million[#]

Board of Directors:

Sue MacLeman

Dr Jane Ryan

Dr Tracie Ramsdale

Dr David Brookes

Management:

Steve Lydeamore, CEO

Dr Tracey Brown, CDO

Dr Michael West, COO

Product Development

Advisory Board:

Prof Peter Gibson

Dr Rebecca Burgell

Dr Jakob Begun

Laureate Prof Nick Talley

Prof Jane Andrews

Prof Barry Campbell

Assoc Prof Simon Keely

Investment highlights: multiple shots on goal

Human health asset, GaRP:

- Aimed at restoring and maintaining **gut health** with **excellent** (pre-clinical *in vitro* and *in vivo* animal studies) **data**
- **Human clinical study** protocol anticipated **late 2019** with a view to commencement in **2Q 2020**
- View to a **partnering deal** by 2H 2020

Animal health asset, Detach®:

- Asset developed for control of scour in piglets
- Well positioned in the livestock market which is in urgent need of non-antibiotic solutions
- Targeting international animal health partner(s) to **license and commercialise Detach®** by **end FY 2020**


Detach[®] Next Steps

Detach[®] increases survivability and provides health benefits to pre-weaning piglets

- Growing demand for non-antibiotic solutions for livestock health
- APVMA approved
- Secure international animal health partner(s) by end **FY 2020**
 - discussions underway with several multinational organisations
 - regulatory approval of Detach[®] in key **overseas markets**
 - opportunity to fast track registration in SE Asia
 - develop **new formulations** and administration methods for Detach[®] to **expand utility**
 - develop Detach[®] for **other livestock species**, such as poultry



Burgeoning microbiome market: our first targets



Profound impact on patients

"I feel teary eyed when I have to tell you this. It really does stop you from a lot of things in life like going away – you're always afraid that something's going to happen. Or if I do go away – where is the closest hospital? And am I going to ruin everybody's good time?"

Canadian IBS patient¹

IBS and IBD in a minute

11%

IBS affects around 11% of the global population²



> 5m

With accelerating incidence, IBD has an estimated >5million sufferers worldwide³



- Patients experience **symptoms** such as **pain, bloating and diarrhoea**
- Pharmacological treatment options remain limited and often leave patients with symptoms that are **not well controlled**⁴
- **45%** of IBS-D patients agreed with the statement “I’m willing to try anything to help manage my IBS”⁵



- Up to **50%** of IBS/IBD patients turn to **dietary supplements, complementary and alternative medicines**^{6,7}
- Health-care practitioners increasingly recommend the use of such supportive treatments⁸
- For example, **source of recommended use of Iberogast: Healthcare provider 39.4%**⁹

Major Consumer Health Opportunity



US \$5b OTC** digestive remedies⁹



US \$3b GI* supplement sales¹⁰



US \$5.7b

Global probiotic supplement sales¹¹

Other GI supplements



Iberogast® (Bayer) sales (Germany):
US\$145m¹¹

OTC digestive supplements



Buscopan® (Sanofi) sales (Global):
US\$220m¹²

(OTC only, excludes prescription sales)


Probiotic supplements



Align® (P&G) sales (U.S.):
US\$171.9m¹¹

3 primary underlying factors of IBS and IBD

How are these addressed?




***G**astrointestinal **ReP**rogramming (**GaRP**) dietary supplement

Changing the game for IBS and IBD


Gastrointestinal ReProgramming (GaRP) dietary supplement

- Grounded in scientific evidence
- Regenerative, multi-component dietary supplement
- Triple-targeted therapeutic approach
 - *anti-adhesion;*
 - *anti-inflammatory;*
 - *mucosal regeneration*
- Dual targeted formulation, delivering components to where they can be most effective
- Positioned as either an adjunct to existing therapies, or a sole therapy for IBS



Before

- **Microbial imbalance**
 - Excess pro-inflammatory bacteria
- **Compromised gut integrity**
 - Excess inflammation proteins
 - Gut permeability
- **Damaged mucosal layer**



During

- **Rebalance microbiome**

- Inhibition of attachment and invasion of pro-inflammatory bacteria


- **Restore gut integrity**

- Inhibition of pro-inflammatory proteins
- Reduction in colon inflammation

- **Regenerate mucosal layer**

- Increased mucin gene expression to promote mucosal healing


GaRP gut repair in action



After

- Rebalanced microbiome
- Restored gut integrity
- Regenerated mucosal layer

GaRP regenerated gut



GaRP has been shown to.....

- **Address the dysbiosis of the microbiome**

- Inhibiting the attachment and invasion of pro-inflammatory bacteria by **>95%**






- **Reduce gut inflammation**

- Reducing the production of pro-inflammatory proteins by **>85%**
- Reducing colon inflammation and disrupted bowel habits by **2.5-fold** in mice
- Potential to reduce immunosuppressive dosing in IBD when GaRP used as an adjunct to prescription immunosuppressants

- **Promote mucosal healing**

- Upregulating the expression of mucin genes (MUC2 and MUC6) that are normally downregulated in both IBD and IBS
- Increasing the expression of mucin genes by a factor of **5 to 7-fold** (MUC2 and MUC6 genes)

Anticipated Milestones

	2018 H1	2018 H2	2019 H1	2019 H2	2020 H1	2020 H2
GaRP commercial feasibility	✓					
Patent Application filed		✓				
<i>In vitro</i> GaRP proof of concept - anti-inflammation - anti-attachment			✓ ✓			
<i>In vitro</i> GaRP proof of concept - mucosal healing				✓		
GaRP animal study (IBD) - first cohort - second cohort				✓ 		
Human clinical study (IBS) - pre-trial activities - Study protocol - Commencement				✓ 		
Partnering discussions - Detach® partnering deal - GaRP partnering deal						

Note: In addition to the anticipated milestones above, Anantara is exploring options to build marketing capability and pipeline for selected markets





Contact Anatara Lifesciences Ltd

Steven Lydeamore, CEO

+61 438 027 172

slydeamore@anatara.com

www.anataralifesciences.com

@AnataraANR



anatara-lifesciences-ltd



ANATARA LIFESCIENCES